Pfizer Inc. (PFE) Stock: Surge as EMA Validates Lyme Vaccine Application After Strong Phase 3 Results
TLDR
- Pfizer stock trades near $26.78 as EMA accepts its Lyme vaccine application.
- Pfizer’s Lyme vaccine showed more than 70% efficacy in the Phase 3 VALOR trial.
- EMA validation starts the formal review process for Pfizer’s Lyme vaccine candidate.
- Pfizer and Valneva target a disease affecting over 100,000 Europeans each year.
- PF-07307405 could become Europe’s first approved human vaccine against Lyme disease.
Pfizer (PFE) stock traded almost flat in pre-market trading after European regulators accepted its Lyme disease vaccine application. PFE traded at $26.78, down 0.07%, after closing the previous session at $26.80. The regulatory milestone follows encouraging Phase 3 results showing vaccine efficacy above 70%.
Pfizer Stock Gets Regulatory Boost From EMA Validation
Pfizer and Valneva said the European Medicines Agency validated their Marketing Authorization Application for PF-07307405. The validation allows the EMA to begin formally assessing the companies’ experimental Lyme disease vaccine. Pfizer would manufacture and commercialize the vaccine if regulators eventually approve the candidate.
… Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
